medwireNews: Durvalumab has been approved by the US FDA for the first-line treatment of extensive-stage small-cell lung cancer (SCLC) in combination with etoposide and carboplatin or cisplatin.
The PD-L1 inhibitor should be administered at a dose of 1500 mg every 3 weeks immediately before beginning chemotherapy on a 3-week cycle and then every 4 weeks thereafter.
The approval is based on the findings of the CASPIAN open-label trial which demonstrated a significant overall and progression-free survival gain with durvalumab plus chemotherapy versus chemotherapy alone in this patient population, as well as an improvement in patient-reported outcomes.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group